Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
ImmunityBio announced a commercial partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia and, over time, across the wider Middle East and North Africa, backed by an SFDA registration certificate with pricing. It’s not a new label approval, but it is a concrete step in the global monetization of the ANKTIVA franchise.
Pure-play Earth observation and satellite delivery name listed on Nasdaq, riding a wave of new government contracts and capital raises. This report looks at the real size of the backlog, the evolving mix between satellite sales and data-as-a-service, the cash runway after multiple offerings, and where the risk/reward sits for event-driven traders.
After crossing 1 billion dollars in annual revenue and reporting record gross margins, Tandem enters 2026 in a delicate transition phase: rolling out a pay-as-you-go pharmacy model, expanding direct international operations and pushing its Control-IQ+ automation to more patients, while still carrying net losses and a sizeable convertible note stack.
Solid Biosciences Inc. (NASDAQ: SLDB) is a precision genetic medicines company developing AAV‑based gene therapies for rare neuromuscular and cardiac diseases, with a lead focus on Duchenne muscular dystrophy (DMD), Friedreich’s ataxia (FA), and catecholaminergic polymorphic ventricular tachycardia (CPVT)
Supersonic test platform based at NASA Kennedy Space Center, no meaningful revenue yet, big ambitions on STARLAUNCH and a valuation already pricing in a lot of execution.
From “space small cap in free fall” to one of the most aggressive re-ratings in the space-tech universe, powered by defense demand, sovereign satellite deals and the shift from imagery to full-stack AI analytics.
Quick EN/IT follow-up after the U.S. Court of Appeals for the Federal Circuit upheld the New Jersey decision that Teva’s proposed generic Korlym does not infringe two Corcept patents, clearing a key legal hurdle for generic competition. We look at what this means for Korlym cash flows, how it interacts with the recent relacorilant CRL and why the ovarian cancer PDUFA remains the central medium-term catalyst.
A deep dive into Hims & Hers after the GLP-1 “pill gambit”, the Novo Nordisk lawsuit, and the transformative acquisition of Eucalyptus: business model, financials, balance sheet, insiders, retail crowd and key catalysts for 2026–2027
RCAT has a small analyst following relative to larger defense primes, but those who do cover the name generally frame it as a high-risk, high-reward play on secure U.S. and allied drone demand. Consensus ratings tilt toward “buy” or “speculative buy” in many summaries, with target prices that imply substantial upside from depressed levels – but also embed assumptions about revenue ramp and contract wins that are far from guaranteed.
Israeli business media report that Ondas has submitted an offer to buy Aeronautics, the unmanned systems subsidiary of Rafael. It is a proposal under review, not a completed acquisition. Below: what is confirmed, the political and regulatory risk, and how retail traders are reacting.
NASDAQ: GRCE · Biotech · aSAH / nimodipine IV Grace Therapeutics (GRCE) – GTx-104 and the 2026 FDA Decision Deep dive on Grace Therapeutics ahead of the April 23, 2026 PDUFA date for GTx-104, the company’s IV nimodipine for aneurysmal…
The company says this is its first successful net-based interception at that speed, positioning DefendAir for “on-the-move” protection against fast FPV-style threats and other tactical drones.
Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO.
NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue.
Next business catalyst
Late February 2026 – expected Q4 2025 earnings and business update, with more detail on 45X tax credit monetization, Giga America ramp and FEOC-compliant sourcing.
SpaceX launches satellites, Starlink keeps front lines online, X shapes the information space, and xAI’s Grok is being wired into military networks. A new Pentagon contest for voice-controlled autonomous drones shows how these pieces are starting to lock together into a single, highly political war-tech stack.
Positive 52-week SOL-1 data position AXPAXLI as a potential long-acting option versus aflibercept, yet the stock sells off as investors question trial design, real-world relevance and the regulatory path.
From heavily leveraged roll-up to cash-rich, debt-free federal contractor: what changes after the last note payoff, how the Navy “Big 3” contracts reshape visibility, and what still can go wrong for shareholders.
European Commission Grants Final Conditional Marketing Authorization for ANKTIVA® in EU
Decision C(2026)1197: Final, binding authorization allowing commercial launch across 27 EU member states + Iceland, Norway, Liechtenstein for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Two items in one tape-read: (1) a fresh BusinessWire update on Saudi regulatory engagement (rBCG dossier + ANKTIVA/CPI expansion discussions), and (2) a sell-side note in circulation reiterating a $24 price target from D. Boral Capital (note dated Jan 13, 2026 in the sources below).